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Abstract 
Posterior cortical atrophy (PCA) is characterized by core visuospatial and 
visuoperceptual deficits, and predominant atrophy in the parieto-occipital cortex. The 
most common underlying pathology is Alzheimer’s disease. Existing diagnostic 
criteria suggest that episodic memory is relatively preserved. The aim of this study 
was to examine memory performance at initial clinical presentation in PCA, 
compared to early-onset AD patients (EOAD). 15 PCA patients and 32 EOAD 
patients, and 34 healthy controls were entered into the study. Patients were tested on 
the Addenbrooke’s Cognitive Examination (ACE-R), consisting of subscales in 
memory and visuospatial skills. PCA and EOAD patients were significantly impaired 
compared to controls on the ACE total score (p<.001), visuospatial skills (p<.001) 
and memory (p<.001). Consistent with the salient diagnostic deficits, PCA patients 
were significantly more impaired on visuospatial skills compared to EOAD patients 
(p<.001). However, there was no significant difference between patient groups in 
memory. Further analysis of learning, recall and recognition components of the 
memory subscale showed that EOAD and PCA patients were significantly impaired 
compared to controls on all three components (p<.001), however, there was no 
significant difference between EOAD and PCA patients. The results of this study 
show that memory is impaired in the majority of PCA patients at clinical 
presentation. The findings suggest that memory impairment must be considered in 
assessment and management of PCA and second. Further study into memory in PCA 
is warranted, since the ACE-R is a brief screening tool and is likely to underestimate 
the presence of memory impairment.  
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Introduction 
Proposed diagnostic criteria for posterior cortical atrophy (PCA) [14, 20] emphasize 
core visuospatial and visuoperceptual deficits, not attributable to ocular disease. 
Predominant atrophy is in the parieto-occipital cortex, with relative sparing of the 
temporal regions. The most common underlying pathology is Alzheimer’s disease 
(AD) [1, 9, 18]. Episodic memory is thought to be relatively preserved in PCA. It is 
suggested that anterograde memory is not impaired in the early stages, but gradually 
deteriorates with progression of disease [14, 15]. As a result, memory has rarely been 
examined systematically in PCA. Where memory assessments have been reported, the 
findings have been variable. Comparing PCA with typical AD (tAD), in which the 
hallmark feature is one of early and profound episodic memory impairment, 
McMonagle et al. [14] found that PCA patients scored lowest on measures of 
visuoconstruction, as expected, but in addition there was no significant difference 
compared with tAD on measures of memory. PCA patients achieved less than half the 
maximum score on memory testing, similar to tAD performance. Similarly, Charles 
and Hillis [4] found that memory, as assessed by a verbal list learning task, was 
impaired in both PCA and tAD patients, although tAD patients showed greater 
impairment on delayed recall. Conversely, Kas et al. [10] found that PCA patients 
performed significantly better than tAD patients on an episodic verbal memory test, 
on both free and cued recall components. The variable findings could be due to 
differences in disease duration, however Kas et al. [10] divided PCA patients into 
short (≤3 years) and long (>3 years) disease duration groups, and reported no 
significant differences in neurological or neuropsychological symptoms between the 
two PCA groups. Each of these studies also administered different memory tests, and 
in different sample sizes, which may also explain the discrepant findings.  
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Misdiagnosis in PCA is common due to the relative rarity of presentation and unusual 
symptoms. Patients frequently describe a plethora of referrals and procedures 
undertaken by opticians and opthalmologists in the belief that an ocular abnormality 
accounts for the visual deficits experienced. Equally common are patients presenting 
with an accompanying mood disorder which is then wrongly considered to be the 
primary diagnosis [5]. The presence of mild or even more prominent memory 
impairment early in PCA may assist in the recognition and diagnosis of PCA and 
prevent delays in diagnosis.  
 
The aim of this study was to examine memory performance in PCA patients at initial 
clinical presentation to a cognitive disorders clinic, compared to early-onset AD 
(EOAD) patients with a typical memory impaired presentation.  
 
Materials and methods 
Participants 
All patients were assessed at clinical presentation at the Oxford Cognitive Disorders 
Clinic, Oxford, UK; Wessex Cognitive Disorders Clinic, UK, or the Frontotemporal 
Dementia Clinic, Sydney, Australia. A total of 47 patients were entered into the study: 
15 with PCA and 32 with EOAD. Patient performance was compared to 34 healthy 
controls. Healthy controls were all recruited from the Frontotemporal Dementia 
Clinic, Sydney, Australia. All patients were assessed by a senior behavioural 
neurologist (CB, ST, MH, CK or JRH). PCA patients fulfilled available consensus 
criteria [14, 20]: patients displayed any of the core features of simultanagnosia with or 
without optic ataxia or ocular apraxia, constructional apraxia, visual field defect, 
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elements of Gerstmann’s syndrome or environmental disorientation, with any of the 
supportive features of alexia, ideomotor or dressing apraxia, or prosopagnosia. EOAD 
[13] patients were all under the age of 65 at presentation. Patients underwent either an 
MRI or CT scan where MR was contraindicated (e.g. by a cardiac pacemaker), within 
6 months of presentation. Imaging results were consistent with diagnosis. The study 
was approved by the South Eastern Sydney and Illawarra Area Health Service and the 
University of New South Wales human ethics committees, the National Research 
Ethics Service South Central  - Hampshire B and Oxford C. All participants or their 
Person Responsible provided written informed consent in accordance with the 
Declaration of Helsinki. The genetic status of all patients was unknown. 
  
Cognitive testing 
Patients were tested on the Addenbrooke’s Cognitive Examination-Revised (ACE-R; 
[16]), a widely used screening tool that is administered to all patients at presentation 
to the memory clinics. The ACE-R incorporates tests of memory, attention and 
orientation, language, fluency and visuospatial skills. The memory sub-score of the 
ACE-R consists of learning of a name and address and recall and recognition of this 
information approximately 15 minutes later.  There are also questions testing short-
term memory by asking participants to recall three words, and remote memory testing 
recall to description of the names of famous politicians. 
 
Statistical analysis 
Normality of distribution of the data was examined using Shapiro-Wilk tests. Group 
differences in demographic, clinical and cognitive characteristics were examined 
using one-way analysis of variance, or with Kruskal-Wallis with pairwise 
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comparisons performed using Mann-Whitney tests where assumptions for parametric 
tests were not met. An independent sample t-test was used to examine differences in 
symptom duration. Two-tailed tests were conducted with alpha level set at 0.05. 
 
Results  
Demographic and clinical characteristics 
The demographic and clinical characteristics of patients are shown in Table 1. There 
were no significant differences in age or education. Patients were matched on 
symptom duration. 
 
-Table 1 here- 
 
Memory and visuospatial scores 
Results of group comparisons on the ACE subscales are given in Table 2 and 
graphically represented in Figure 1. Both PCA and EOAD patients were significantly 
impaired compared to controls on the ACE total scores (p<.001), on visuospatial 
skills (p<.001) and on memory (p<.001). 
 
There was no significant difference between patient groups on ACE total score 
(p=.262). As expected, PCA patients were significantly more impaired on visuospatial 
skills compared to EOAD patients (p<.001), in accordance with the salient diagnostic 
deficits in this group. However, there was no significant difference between patient 
groups (p=.619) on the memory subscale. Figure 1 shows that the range of memory 
scores was similar in PCA and EOAD, patients with the majority of both patient 
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groups scoring below the control range. Visuospatial scores were consistently low in 
PCA patients compared with controls, but more variable in EOAD. 
 
-Table 2 here- 
-Figure 1 here- 
 
Further analysis was conducted of the main constituents of the ACE-R memory score, 
in a subset of the patient (n=30) and control (n=34) sample for whom data was 
available. This consists of learning a name and address, recalling the information after 
delay (typically 10 minutes, depending on the speed of the patient), and finally a 
recognition test of any items not recalled. Table 3 shows that both EOAD and PCA 
patients were significantly impaired compared with controls on all three of the 
memory components (p<.001), however, there was no significant difference between 
EOAD and PCA patients.  
 
-Table 3 here- 
 
Clinical profile of PCA patients 
Further data from each of the 15 PCA patients at initial presentation are shown in 
Table 4. Clinical characteristics were consistent with the core features of PCA [20]. 
Memory impairment (based on the ACE-R memory sub-score and classed as 2+ 
standard deviations below the control mean) was evident in 10 of the 15 PCA patients 
assessed (66.7%). There was no significant difference between these memory 
impaired PCA patients and those with preserved memory, in terms of age, education 
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or disease duration. Of the PCA patient with memory impairment, scores for 9 out of 
10 of PCA patients (90%) fell within the range of EOAD scores.  
 
-Table 4 here- 
 
Discussion 
Diagnostic criteria for PCA have emphasized salient visual deficits in the absence of 
ocular disease, and preserved or only mildly impaired episodic memory. 
Consequently, memory has rarely been systematically examined in PCA and the few 
studies that have included memory assessment report variable findings [4, 10, 14]. 
The results of this study show that memory is often impaired in PCA patients at 
clinical presentation. 66.7% of PCA patients had impaired memory compared to 
healthy controls, suggesting that early memory impairment is common, although not 
ubiquitous in PCA. Furthermore, while PCA patients could be characterized by salient 
and significant deficits in visuospatial features compared to controls and EOAD 
patients, memory was also impaired in PCA. The mean scores were indistinguishable 
between the two patient groups. Early impairment in memory alongside the defining 
visual disturbances, is consistent with the handful of past studies that have included 
simple memory measure in the neuropsychological assessment [4, 14]. However, the 
reasons for impairment are not clear. We propose three possible explanations. 
 
Firstly, impairment may be driven by the primary pathology in the parietal cortex, 
specifically affecting attentional networks underlying memory. In task-based 
neuroimaging studies, the posterior parietal cortices are frequently activated in 
response to episodic memory retrieval [3]. A meta-analytic review [19] identified the 
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parietal lobes as being more consistently activated during recollection, identified in 
90% of studies reviewed, compared to more typically considered episodic memory 
regions such as the medial temporal lobe. Neuropsychological studies of patients with 
bilateral parietal lobe lesions have found that patients are impaired on tests of 
recollection, such as autobiographical memory retrieval [2] or remember/know 
paradigms [7], and provide few ‘remembered’ responses, and lack of specificity and 
richness of freely recalled autobiographical events.  
 
Secondly, PCA patients may have more widespread pathology extending to medial 
temporal memory-related structures. Tang-Wai et al. [20] described a group of PCA 
patients in detail to form the basis of currently used diagnostic criteria, and found 
relatively preserved medial temporal lobe structures, which could be appreciated 
antemortem on MRI scans. Conversely, Migliaccio et al. [15] found that regions of 
grey matter reduction in PCA included the hippocampus bilaterally. Studies 
examining cortical thickness patterns have also reported reductions in the medial 
temporal lobe [12]. The majority of our patients presented within 2-3 years of 
symptom onset, and imaging was consistent with salient parieto-temporal atrophy. 
However, more detailed imaging analysis may have highlighted more extensive 
deficits. 
 
A third possibility is that verbal memory impairment may be attributable to disruption 
of language networks in the left hemisphere.  A recent study described subtle 
language impairments in PCA characterized by anomia, poor phonemic fluency and 
slow speech rate, resembling the linguistic profile most consistent with logopenic 
aphasia [6]. Language was not assessed in detail at clinical presentation in the PCA 
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patients reported in this study. However, it is worth noting the PCA patients assessed 
in Crutch et al. [6] had an average symptom duration of 6 years, more than twice that 
of the majority of PCA patients in this study, and thus it is suggested that language 
impairment may be a feature of more advanced stages of PCA. 
 
A small percentage of PCA patients scored within the control range. These patients 
were comparable to the impaired PCA group in age, education and, importantly, in 
symptom duration. Preserved memory in this small group may be due to individual 
variation in disease expression, or due to the insensitivity of the ACE-R to subtle 
memory impairment.  
 
There are limitations to this study. The ACE-R is a brief screening tool and was used 
to demonstrate that memory impairment can be detected in PCA with a broad measure 
at presentation. The ACE-R is likely therefore to underestimate the extent of memory 
impairment. It is also unable to provide detailed information as to the nature of 
episodic memory impairment in PCA and EOAD. Further investigation with detailed 
neuropsychological testing of memory function in PCA is therefore essential. 
However, the results support the conclusion that memory impairment can be detected 
at initial presentation with a simple screening instrument, and with a relatively short 
average symptom duration compared to other studies (for example, [6, 10]). Despite 
differences in the predominant clinical symptoms in PCA and EOAD, the 
concomitant and significant memory impairment early in the clinical course may 
reflect the common underlying AD pathology. A similar finding has been reported in 
an earlier study, examining patients with logopenic aphasia (lv-PPA), characterized 
by impaired repetition of sentences and naming and in which the underlying 
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pathology is AD in the majority of patients. Flanagan et al. [8] found that lv-PPA 
patients were significantly impaired in memory, and did not differ from a tAD group, 
suggesting that identifying specific impairments in memory may supplement 
diagnosis of patients with pathology.  
 
 These findings have clear clinical implications. Current diagnostic criteria emphasize 
the relative preservation of memory in PCA, yet the findings provide evidence of a 
detectable memory deficit early in the course of disease. Further study is warranted to 
determine how diagnostic criteria may need to be revised.  Diagnostically, the 
presence of memory impairment may assist in the early identification of PCA, helping 
to differentiate from visual disturbances caused by ocular or other problems. 
Improving our understanding of more focal presentations of AD is imperative to 
facilitate accurate prediction of AD pathology in life, and support the development of 
target therapies for AD. Studies suggest that variant clinical presentations of AD are 
not so infrequent, representing a third of patients with early-onset AD, and at least 5% 
of late onset cases [11]. In terms of intervention and management, while it is entirely 
appropriate to centre care and advice on the critical visual impairments experienced 
by patients, it is also important to consider problems arising from memory 
impairment. The literature on tAD cites extensive examples of the pervasive 
difficulties memory impairment incites, e.g. in restricting activities of daily living 
[17]. Memory impairment therefore must be considered in assessment and 
management of PCA.  
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 Normal 
controls 
(n=34) 
 
EOAD 
(n=32) 
 
PCA 
(n=15) 
 
p 
Age at onset 59.8 
(3.9) 
57.5 
(5.3) 
59.5 
(6.9) 
n.s. 
Education  13.7 
(2.9) 
13.4 
(2.4) 
12.3* 
(2.0) 
n.s. 
Gender (m:f) 17:17 15:17 7:8 - 
Symptom duration 
(yrs) 
- 2.6 
(1.2) 
2.4 
(0.86)
 
n.s. 
  EOAD Early onset AD; PCA Posterior cortical atrophy 
  
*
N=17 data regarding education unavailable for one patient. 
 
 
Table 1. Demographic and clinical characteristics of patient groups and controls.  
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 Normal 
controls 
(n=34) 
 
EOAD 
(n=32) 
 
PCA 
(n=15) 
 
Omnibus 
p 
ACE-R Memory (26) 24.3 
(1.9) 
13.2
a 
(5.0) 
16.1
a 
(6.0) 
<.001 
ACE-R Visuospatial (16) 15.4 
(1.0) 
10.9
a,b 
(4.0) 
7.1
a 
(3.7) 
<.001 
ACE-R Total (100) 94.7 
(3.1) 
65.5
a 
(15.1) 
66.4
a 
(12.7) 
<.001 
ACE-R Addenbrooke’s Cognitive Examination-Revised; EOAD Early onset AD; PCA 
Posterior cortical atrophy 
a
Significant difference compared to controls p<.001 
b
Significant difference compared to PCA p<.001 
 
 
Table 2. Group scores on the Addenbrookes’s Cognitive Examination-Revised (ACE-
R).  
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 Normal 
controls 
(n=34) 
 
EOAD 
(n=14) 
 
PCA 
(n=16) 
Omnibus 
p 
ACE-R learning (7) 7.0 
(0.1) 
4.9
a 
(2.2) 
5.4
a 
(1.7) 
<.001 
ACE-R recall (7) 5.9 
(1.3) 
1.4
a 
(1.7) 
1.9
a
 
(2.5) 
<.001 
ACE-R recognition (5) 4.7 
(0.5) 
3.6
a
 
(0.6) 
3.6
a
 
(1.1) 
<.001 
ACE-R Addenbrooke’s Cognitive Examination-Revised; EOAD Early onset AD; PCA 
Posterior cortical atrophy 
a
Significant difference compared to controls p<.001 
 
 
Table 3. Group scores on the ACE-R memory questions 
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PCA patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Demographics                
Age at onset (yrs) 51 76 63 55 58 57 61 54 63 56 63 48 57 65 66 
Gender  F M F F M M M F F M M F F M F 
Symptom duration (yrs) 2.0 2.5 2.0 1.0 1.2 3.0 2.0 2.5 2.0 2.0 4.0 1.8 2.5 3.0 4.0 
ACE Total 76 78 54 69 63 76 55 75 78 79 85 53 51 45 59 
Core features (Tang-Wei et al. 2004) 
 Any of the following: 
               
Simultanagnosia with or without optic 
ataxia or ocular apraxia 
 + + +     + + + + + + + 
Constructional apraxia +    + + + + +  + + + + + 
Visual field defect + +   + +  +      + + 
Elements of Gerstmann’s syndrome +   + + + +   +      
Environmental disorientation  +              
Supportive features (Tang-Wei et al. 
2004): 
               
Alexia  + +     + +    +  +  
Ideomotor or dressing apraxia   + + +  +    + +  + + 
Prosopagnosia              +   
Imaging consistent with PCA + + + + + + + + + + + + + + + 
Memory                
Memory impairment (based on ACE-R 
memory subscore) 
- + + + + - + + - - - + + + + 
 
Table 4. Individual case analysis of 15 PCA patients. 
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Figure 1. Scatterplots representing individual ACE-R memory and visuospatial scores for controls (NC), early onset AD (EOAD) and PCA 
(posterior cortical atrophy) patients.  
 
 
 
